The TRAIL apoptotic pathway in cancer onset, progression and therapy - PubMed (original) (raw)
Review
doi: 10.1038/nrc2465.
Affiliations
- PMID: 18813321
- DOI: 10.1038/nrc2465
Review
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Ricky W Johnstone et al. Nat Rev Cancer. 2008 Oct.
Abstract
Triggering of tumour cell apoptosis is the foundation of many cancer therapies. Death receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized, as have the signals that are generated when these receptors are activated. TNF-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility of recombinant TRAIL and agonistic antibodies against TRAILR1 and TRAILR2.
Similar articles
- Therapeutic targeting of CD95 and the TRAIL death receptors.
Gerspach J, Pfizenmaier K, Wajant H. Gerspach J, et al. Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):294-310. doi: 10.2174/157489211796957739. Recent Pat Anticancer Drug Discov. 2011. PMID: 21762072 Review. - Targeting death-inducing receptors in cancer therapy.
Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Takeda K, et al. Oncogene. 2007 May 28;26(25):3745-57. doi: 10.1038/sj.onc.1210374. Oncogene. 2007. PMID: 17530027 Review. - Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E, Takeda K, Smyth MJ. Cretney E, et al. Int J Biochem Cell Biol. 2007;39(2):280-6. doi: 10.1016/j.biocel.2006.10.005. Epub 2006 Oct 7. Int J Biochem Cell Biol. 2007. PMID: 17097329 Review. - TRAIL as a target in anti-cancer therapy.
Wu GS. Wu GS. Cancer Lett. 2009 Nov 18;285(1):1-5. doi: 10.1016/j.canlet.2009.02.029. Epub 2009 Mar 18. Cancer Lett. 2009. PMID: 19299078 Review. - From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
Cordier SM, Papenfuss K, Walczak H. Cordier SM, et al. Results Probl Cell Differ. 2009;49:115-43. doi: 10.1007/400_2008_27. Results Probl Cell Differ. 2009. PMID: 19142621 Review.
Cited by
- Enriching the human apoptosis pathway by predicting the structures of protein-protein complexes.
Acuner Ozbabacan SE, Keskin O, Nussinov R, Gursoy A. Acuner Ozbabacan SE, et al. J Struct Biol. 2012 Sep;179(3):338-46. doi: 10.1016/j.jsb.2012.02.002. Epub 2012 Feb 14. J Struct Biol. 2012. PMID: 22349545 Free PMC article. - Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.
Flusberg DA, Sorger PK. Flusberg DA, et al. Phys Biol. 2013 Jun;10(3):035002. doi: 10.1088/1478-3975/10/3/035002. Epub 2013 Jun 4. Phys Biol. 2013. PMID: 23735516 Free PMC article. - Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Zhitao J, Long L, Jia L, Yunchao B, Anhua W. Zhitao J, et al. Tumour Biol. 2015 Dec;36(12):9621-30. doi: 10.1007/s13277-015-3720-8. Epub 2015 Jul 6. Tumour Biol. 2015. PMID: 26142735 - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2).
Werneburg NW, Bronk SF, Guicciardi ME, Thomas L, Dikeakos JD, Thomas G, Gores GJ. Werneburg NW, et al. J Biol Chem. 2012 Jul 13;287(29):24427-37. doi: 10.1074/jbc.M112.342238. Epub 2012 May 29. J Biol Chem. 2012. PMID: 22645134 Free PMC article. - Interactions of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer.
Beyer K, Baukloh AK, Stoyanova A, Kamphues C, Sattler A, Kotsch K. Beyer K, et al. Cancers (Basel). 2019 Aug 13;11(8):1161. doi: 10.3390/cancers11081161. Cancers (Basel). 2019. PMID: 31412671 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources